Abstract
Ten HIV-infected nucleoside reverse transcriptase inhibitor-treated subjects with lipoatrophy or sustained hyperlactatemia were given antioxidants: vitamins C, E, and N-acetyl cysteine. After 24 weeks, anthropometrics did not change significantly, except for a modest decrease in the waist-to-hip ratio. Fasting low-density lipoprotein cholesterol trended toward lower values. Fasting glucose significantly increased along with a significant increase in homeostatic model assessment values, reflecting an increase in insulin resistance. Controlled trials are required to evaluate directly the effects of these agents on lipid and glucose metabolism.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetylcysteine / therapeutic use
-
Adult
-
Antioxidants / therapeutic use*
-
Ascorbic Acid / therapeutic use
-
Body Composition
-
Cholesterol / blood
-
Female
-
Glucose / analysis
-
Glucose / metabolism*
-
HIV-Associated Lipodystrophy Syndrome / chemically induced
-
HIV-Associated Lipodystrophy Syndrome / drug therapy*
-
HIV-Associated Lipodystrophy Syndrome / metabolism
-
Hospitals, University
-
Humans
-
Lipids / blood
-
Male
-
Middle Aged
-
Ohio
-
Pilot Projects
-
Reverse Transcriptase Inhibitors / adverse effects
-
Reverse Transcriptase Inhibitors / therapeutic use
-
Vitamin E / therapeutic use
Substances
-
Antioxidants
-
Lipids
-
Reverse Transcriptase Inhibitors
-
Vitamin E
-
Cholesterol
-
Glucose
-
Ascorbic Acid
-
Acetylcysteine